×

Still upside in Eli Lilly despite drug failure: Divan

3:20 PM ET Wed, 23 Nov 2016

Vamil Divan, Credit Suisse senior analyst, discusses Eli Lilly's failed Alzheimer's drug trial and the effect on its stock price.